Literature DB >> 31515568

[Neuroendocrine tumors of the stomach, duodenum and pancreas : Value of (hybrid) radiological diagnostics].

J Rübenthaler1,2, C Auernhammer3,4, I Harun5,4, J Ricke6,4, C C Cyran6,4.   

Abstract

CLINICAL/METHODICAL ISSUE: Neuroendocrine tumors (NET) of the stomach, duodenum and pancreas are rare tumors with a low incidence but the exact tumor localization and staging diagnostics are of critical importance for further planning of treatment. STANDARD RADIOLOGICAL
METHODS: Standard primary diagnostic methods include multimodal imaging with computed tomography (CT) and magnetic resonance imaging (MRI) but in 20-50% of the cases the localization of the primary tumor cannot be identified. METHODICAL INNOVATIONS: Modern hybrid imaging procedures combine radiological procedures and functional imaging, e.g. using somatostatin receptor (SSR) positron emission tomography CT (PET)/CT imaging. For the exact diagnostics of the primary tumor and distant metastases morphological and functional aspects can be combined for targeted diagnostics. For primary tumor staging a sensitivity of 80.0% and a specificity of 88.4% are given in the literature. PERFORMANCE: The application of SSR PET/CT led to a change in patient management in 44% of all cases according to a recently published meta-analysis and therefore had a significant influence on the further procedure. ASSESSMENT: The use of SSR PET/CT can provide critical information for further treatment and can lead to a significant change in treatment management in a relevant proportion of patients. PRACTICAL RECOMMENDATIONS: Radiological imaging diagnostics and in particular hybrid functional imaging procedures using PET/CT will become increasingly more relevant for the diagnostics, treatment and follow-up of NET patients.

Entities:  

Keywords:  Neuroendocrine tumors; Patient management; Positron emission tomography; Somatostatin receptor; Tumor localization

Mesh:

Year:  2019        PMID: 31515568     DOI: 10.1007/s00117-019-00593-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Evaluation of Magnetic Resonance (MR) Biomarkers for Assessment of Response With Response Evaluation Criteria in Solid Tumors: Comparison of the Measurements of Neuroendocrine Tumor Liver Metastases (NETLM) With Various MR Sequences and at Multiple Phases of Contrast Administration.

Authors:  Gustavo Felipe Luersen; W Wei; Eric P Tamm; Priya R Bhosale; Janio Szklaruk
Journal:  J Comput Assist Tomogr       Date:  2016 Sep-Oct       Impact factor: 1.826

Review 2.  Neuroendocrine neoplasms of the gastrointestinal tract.

Authors:  Matthias Schott; Günter Klöppel; Andreas Raffel; Andreas Saleh; Wolfram Trudo Knoefel; Werner A Scherbaum
Journal:  Dtsch Arztebl Int       Date:  2011-05-06       Impact factor: 5.594

3.  Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Clemens Decristoforo; Ahmet Araman; Yıldız Ozsoy; Ilhami Uslu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-20       Impact factor: 9.236

Review 4.  The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.

Authors:  Christodoulos P Pipinikas; Alison M Berner; Teresa Sposito; Christina Thirlwell
Journal:  Endocr Relat Cancer       Date:  2019-08-01       Impact factor: 5.678

5.  High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging.

Authors:  Gaspard d'Assignies; Priscilla Fina; Onorina Bruno; Marie-Pierre Vullierme; Florence Tubach; Valérie Paradis; Alain Sauvanet; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Radiology       Date:  2013-03-26       Impact factor: 11.105

6.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Authors:  Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

7.  Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.

Authors:  Ulrich-Frank Pape; Uta Berndt; Jacqueline Müller-Nordhorn; Michael Böhmig; Stephanie Roll; Martin Koch; Stefan N Willich; Bertram Wiedenmann
Journal:  Endocr Relat Cancer       Date:  2008-07-04       Impact factor: 5.678

Review 8.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

9.  Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management.

Authors:  Dushyant V Sahani; Pietro A Bonaffini; Carlos Fernández-Del Castillo; Michael A Blake
Journal:  Radiology       Date:  2013-01       Impact factor: 11.105

10.  Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.

Authors:  Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.